Skip to content

Ketamine Modulates Endogenous Opioid Peptide Signaling and Reduces Heroin-Seeking in Male Long-Evans Rats

Adam Dawoud, Achla Gupta, Ivone Gomes, Dylan Baker, Julia E Shapiro, Lakshmi A Devi, Yasmin L. Hurd, Aya Osman

bioRxiv (Cold Spring Harbor Laboratory) September 6, 2026 preprint DOI: 10.64898/2026.09.01.748554 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Preclinical experimental study
Population Male Long-Evans rats
Intervention Ketamine
Topics Esketamine Ketamine
Key findings Ketamine increased endogenous opioid gene and peptide expression, mu-opioid receptor protein, and G protein activity, particularly in the nucleus accumbens shell, and altered NMDAR subunit expression. It significantly reduced heroin-primed but not cue-induced seeking, suggesting reduced acute relapse vulnerability.

Abstract

Opioid Use Disorder (OUD) continues to be a pressing public health crisis, marked by high relapse rates and limited treatment options. Ketamine, a non-competitive N-Methyl-D-Aspartate receptor (NMDAR) antagonist, has emerged as a promising therapeutic for numerous psychiatric illnesses due to its robust antidepressant properties and glutamate-mediated synaptic plasticity. However, ketamine's therapeutic mechanisms remain elusive, with emerging evidence implicating the endogenous opioid system. Furthermore, few studies have investigated ketamine's potential as an intervention for OUD. Accordingly, this study assessed ketamine's ability to rewire endogenous opioid and glutamatergic circuitry and reduce heroin-seeking activity in male Long-Evans rats. Using a multi-cohort design, we investigated ketamine's effects on opioid-related transcriptional, protein, and signaling properties in key brain regions associated with reward and addiction, and subsequently on heroin-seeking using a self-administration paradigm. To investigate mechanisms of plasticity, we also quantified transcriptional changes to NMDAR subunits. Molecular analyses demonstrated increased expression of endogenous opioid system-related genes and endogenous opioid peptides at the protein level, elevated mu-opioid receptor protein levels, and enhanced G protein activity, suggesting increased receptor function. Notably, transcriptional changes were particularly prominent in the shell subregion of the nucleus accumbens (NAc). We also revealed that ketamine altered NMDAR subunit expression in the medial prefrontal cortex and NAc, indicating circuit-level synaptic remodeling. Behavioral analyses revealed that ketamine significantly reduced heroin-primed, but not cue-induced, seeking activity. Together, these findings suggest ketamine reduces acute relapse vulnerability to opioids through coordinated modulation of opioid and glutamatergic systems, highlighting its potential as a novel intervention for OUD.